Cancer Genetics and Epigenetics 2024, Vol.12, No.3, 125-136 http://medscipublisher.com/index.php/cge 132 more comprehensive understanding of tumor biology but also adds to the complexity of data interpretation. Additionally, the lack of robust platforms to guide the interpretation of complex genomic data further hinders the effective implementation of precision treatment. In summary, addressing the challenges of tumor heterogeneity, drug resistance, and data interpretation is crucial for advancing the precision treatment of liver cancer. Continued research and the development of innovative strategies are essential to overcome these obstacles and improve patient outcomes (Tsimberidou et al., 2021). 7 Advances in Technology and Methodology 7.1 Next-Generation sequencing Next-Generation Sequencing (NGS) has revolutionized the field of cancer genomics, providing a comprehensive and high-resolution view of the cancer genome. NGS technologies enable the sequencing of large numbers of nucleotides in a short time frame at an affordable cost, making it a valuable tool in both research and clinical settings (Marquardt and Andersen, 2012). The application of NGS in liver cancer has facilitated the identification of somatic and germline mutations, allowing for the classification of tumor subtypes based on genetic alterations (Wakai et al., 2018). This has led to the development of targeted therapies and personalized treatment strategies, which are crucial in the era of precision medicine (Horák et al., 2016). Despite its potential, the implementation of NGS in clinical practice faces several challenges, including the complexity of data interpretation and the need for standardization of sequencing procedures. The European Society for Medical Oncology (ESMO) has proposed recommendations for the use of NGS in oncology practice, emphasizing the importance of multigene panels and the need for quality control in routine NGS-based genomic testing. Additionally, the integration of NGS data with other molecular analyses, such as transcriptomics and epigenomics, holds promise for a more comprehensive understanding of liver cancer pathobiology. 7.2 CRISPR and genome editing CRISPR and other genome editing technologies have emerged as powerful tools for studying and potentially treating liver cancer. These technologies allow for precise modifications of the genome, enabling researchers to investigate the functional roles of specific genes and genetic mutations in cancer development and progression. The combination of CRISPR with NGS can provide critical insights into the genetic and transcriptional heterogeneity of tumors, which is essential for understanding therapeutic resistance and relapse. Genome editing technologies also offer the potential for developing novel therapeutic strategies. For instance, CRISPR can be used to correct genetic mutations or to disrupt oncogenes, thereby inhibiting cancer growth. The integration of CRISPR with other advanced technologies, such as interaction mapping and machine learning, could further enhance our ability to identify and target key regulatory networks involved in liver cancer (Kyrochristos and Roukos, 2019). 7.3 Bioinformatics and data integration The vast amount of data generated by NGS and other high-throughput technologies necessitates the use of advanced bioinformatics tools for data analysis and integration. Bioinformatics plays a crucial role in the interpretation of genomic data, enabling the identification of clinically actionable mutations and the prediction of patient response to targeted therapies (Shyr and Liu, 2013). The development of comprehensive knowledge bases and computational algorithms has facilitated the clinical implementation of NGS, allowing for more informed decision-making in precision oncology (Gagan and Van Allen, 2015). Data integration is also essential for overcoming the challenges posed by tumor heterogeneity and the "noise" in NGS data. By combining genomic, transcriptomic, and epigenomic data, researchers can gain a more holistic view of the molecular mechanisms underlying liver cancer. This integrative approach can help identify novel biomarkers and therapeutic targets, ultimately improving patient outcomes. In conclusion, advances in NGS, CRISPR, and bioinformatics are driving significant progress in the precision treatment of liver cancer. These technologies offer new opportunities for understanding the genetic basis of liver cancer and for developing personalized treatment strategies that are tailored to the unique molecular profiles of individual patients (Morganti et al., 2019). However, the successful implementation of these technologies in clinical practice requires ongoing efforts to address technical challenges and to ensure the standardization and validation of sequencing procedures (Colomer et al., 2020).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==